This discovery extends decursin’s documented anticancer mechanisms beyond colorectal cancer (ROS/ER stress-mediated apoptosis) [27], gastric cancer (CXCR7-STAT3-cMyc axis suppression) [15], and hypoxic lung tumors (HIF-1α destabilization) [14], establishing proteasome-mediated oncoprotein degradation as a novel therapeutic modality in ESCC. This evidence concerns the gene MYC and esophageal squamous cell carcinoma.